openPR Logo
Press release

Remote Patient Monitoring (RPM) Tools To Flood The U.S Bacterial Conjunctivitis Drugs Market

08-19-2022 12:01 PM CET | Health & Medicine

Press release from: Persistence Market Research

Remote Patient Monitoring (RPM) Tools To Flood The U.S Bacterial

According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be the Largest Segment by 2024" the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical).

How About Looking Through The Sample Of U.S Bacterial Conjunctivitis Drugs Market Report? https://www.persistencemarketresearch.com/samples/5192

Major organizations profiled in this report include:

Actavis plc.
Akorn, Inc.
Bayer AG.
F. Hoffmann-La Roche, Ltd.
Merck & Co., Inc.
Novartis AG.
Perrigo Company plc, Pfizer, Inc.
Santen Pharmaceutical Co., Ltd.
Valeant Pharmaceuticals International, Inc.
Additionally.

How About Step-By-Step Insights To U.S Bacterial Conjunctivitis Drugs Market? Look Through The "Methodology" Employed! https://www.persistencemarketresearch.com/methodology/5192

Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.

However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years.

Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.

These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country.

Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013. Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity.

Want To Keep A Tab On The Latest Findings In The U.S Bacterial Conjunctivitis Drugs Market? Purchase Our U.S Bacterial Conjunctivitis Drugs Market Report Now! https://www.persistencemarketresearch.com/checkout/5192

However, the segment is expected to witness a significant decline in sales in the near future -from a CAGR of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major factors that would adversely affect the growth of the segment.

With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications.

However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the novel product pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis.

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Remote Patient Monitoring (RPM) Tools To Flood The U.S Bacterial Conjunctivitis Drugs Market here

News-ID: 2709783 • Views:

More Releases from Persistence Market Research

Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health Trends
Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health …
Overview of the Global Fruit Ingredients Market The global fruit ingredients market is witnessing significant growth, driven by rising consumer demand for natural, clean-label, and nutrient-rich food products. In 2025, the market is likely to be valued at US$ 75.0 billion and is expected to reach US$ 111.3 billion by 2032, registering a robust CAGR of 5.8% during the forecast period. Fruit ingredients, which include fruit concentrates, purees, powders, and extracts,
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Plant-Based Demand
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Pla …
Overview of the Market The global vegan dessert market is poised for significant expansion, with an estimated valuation of US$ 5.2 billion in 2025, projected to reach US$ 11.9 billion by 2032. This robust growth reflects a compound annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2032. Increasing consumer awareness about health, environmental sustainability, and ethical food consumption is driving the widespread adoption of vegan dessert
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenience & Demand
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenienc …
Overview of the Global Instant Beverage Premix Market The global instant beverage premix market has witnessed remarkable growth over the past decade, driven by evolving consumer lifestyles and increasing demand for convenient, ready-to-consume beverages. Instant beverage premixes, encompassing products such as instant coffee, tea, flavored drinks, protein powders, and nutritional supplements, cater to busy consumers seeking quick preparation without compromising on taste or nutritional value. These premixes have gained popularity across
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Market Research
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Mar …
The global dermacosmetics market, estimated at US$ 53 billion in 2025, is forecasted to witness a steady upward trajectory, expanding at a Compound Annual Growth Rate (CAGR) of 7.4% to reach US$ 87.3 billion by 2032. This surge is driven by a confluence of factors ranging from increasing consumer awareness and the rising incidence of skin conditions to a growing preference for advanced, dermatologist-backed skincare solutions. Dermacosmetics, a category that

All 5 Releases


More Releases for Bacterial

Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market? The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training. The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can
02-07-2017 | Health & Medicine
TMR
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as